Journal: Frontiers in Pharmacology
Article Title: Identification and evaluation of a pinocembrin analog as a TRPV1 inhibitor with analgesic properties in murine pain models
doi: 10.3389/fphar.2025.1585181
Figure Lengend Snippet: The effect of PINO on NF-κB and MAPK pathways. RAW264.7 cells were treated with CPZ (10 μM) or PINO (10 μM) for 1 h, and whole-cell lysates were prepared and immunoblotted using p-p65, p65, p-IκBα, IκBα, p-p38, p38, p-JNK, JNK, p-ERK1/2, ERK1/2, TRPV1, β-actin, GAPDH, and β-tubulin antibody (A) . Fold change was determined after normalization with β-actin, GAPDH, or β-tubulin, with the right panels illustrating the fold change relative to the control: p-p65/p65 (B) , p-IκBα/IκBα (C) , p-p38/p38 (D) , p-JNK/JNK (E) , p-ERK1/2/ERK1/2 (F) and TRPV1/β-actin (G) (n = 6). Data are presented as mean ± SD. Statistical analysis by one-way ANOVA with Bonferroni’s post hoc test.
Article Snippet: Phospho-NF-κB p65 (Ser468) antibody, NF-κB p65 antibody, Phospho-IκB Alpha (Ser32/36) antibody, IκB Alpha antibody, Phospho-p38 MAPK (Thr180/Tyr182) antibody, p38 MAPK antibody, Phospho-JNK (Tyr185) antibody, JNK antibody, Phospho-ERK1/2 (Thr202/Tyr204) antibody, ERK1/2 antibody, TRPV1 antibody, β-actin antibody, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody, β-Tubulin and Goat Anti-Rabbit IgG (H + L) were purchased from Proteintech Group, Inc. (Wuhan, China).
Techniques: Control